Cisplatinum rechallenge in relapsed ovarian cancer patients with platinum reinduction therapy and carboplatin hypersensitivity
Version of Record online: 12 SEP 2005
International Journal of Gynecological Cancer
Volume 15, Issue 5, pages 780–784, September 2005
How to Cite
KANDEL, M.J., LOEHR, A., HARTER, P., TRAUT, A., GNAUERT, K. and Du BOIS, A. (2005), Cisplatinum rechallenge in relapsed ovarian cancer patients with platinum reinduction therapy and carboplatin hypersensitivity. International Journal of Gynecological Cancer, 15: 780–784. doi: 10.1111/j.1525-1438.2005.00136.x
- Issue online: 12 SEP 2005
- Version of Record online: 12 SEP 2005
- Accepted for publication May 18, 2004
- hypersensitivity reaction;
- ovarian cancer
Abstract. Kandel MJ, Loehr A, Harter P, Traut A, Gnauert K, du Bois A. Cisplatinum rechallenge in relapsed ovarian cancer patients with platinum reinduction therapy and carboplatin hypersensitivity. Int J Gynecol Cancer 2005;15:780–784.
Hypersensitivity reactions have been reported as limiting side effect in patients reexposed to carboplatin for relapsed gynecologic malignancy. This study analyzed the incidence, clinical features, management, and outcome of carboplatin-associated hypersensitivity reactions. We performed a retrospective study and analyzed medical records of all gynecological cancer patients treated with carboplatin in our institution from 2000 to 2003. No hypersensitivity reactions were observed in 171 patients during the first carboplatin-containing chemotherapy. All six carboplatin-associated hypersensitivity reactions occurred in 69 patients who were reexposed to carboplatin (9%). The median number of carboplatin cycles prior to hypersensitivity reaction was nine (range, 8–13). Cisplatin rechallenge was performed in five patients, and no hypersensitivity occurred. An increase in neurotoxicity (National Cancer Institute Common Toxicity Criteria grade 2) was documented in two patients who had residual neurotoxicity grade 1 due to prior taxane treatment. Cisplatinum rechallenge is a feasible strategy to overcome carboplatin hypersensitivity. However, close monitoring of neurotoxicity is necessary, particularly in patients with residual neurotoxicity due to prior platinum- and taxane-containing chemotherapy.